Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Merit Medical Systems designs, manufactures, and markets medical devices, primarily for interventional radiology, vascular access, and surgical procedures. The company operates in four main product categories: stand-alone devices, custom kits and procedure trays, inflation devices, and catheters.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|---|---|
| Net Sales | $50,584 | $153,425 | $46,697 | $139,858 |
| Gross Profit | $19,783 | $58,178 | $18,068 | $54,115 |
| Gross Margin % | 39.1% | 37.9% | 38.7% | 38.7% |
| Operating Income | $6,086 | $16,037 | $5,136 | $14,317 |
| Net Income | $4,295 | $10,860 | $3,325 | $9,248 |
| Diluted EPS | $0.15 | $0.38 | $0.12 | $0.33 |
| Cash from Operations (9mo) | $21,906 | $14,747 | ||
| Cash & Equivalents (Sep 30, 2007) | $12,199 | $9,838 (Dec 31, 2006) | ||
| Working Capital (Sep 30, 2007) | $55,922 | $54,972 (Dec 31, 2006) | ||
| Current Ratio | 3.7:1 | N/A |
Note: All financial figures are in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% ($3.9M) for the quarter and 10% ($13.6M) for the nine-month period compared to the prior year. Growth was driven by increased sales of inflation devices, stand-alone devices (MCTec, sensor-based products), and catheters (Prelude sheath, Resolve locking drainage, ProGuide).
- Profitability: Net income rose 29% for the quarter and 17% for the nine-month period. Operating income increased 18% (quarter) and 12% (nine months).
- Gross Margins: Q3 2007 gross margin improved to 39.1% from 38.7% in Q3 2006, attributed to production efficiencies, product mix improvements, and automation. However, the nine-month margin decreased slightly to 37.9% due to higher wages, headcount increases, and inventory obsolescence.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (23.1% vs 23.2% in Q3; 23.2% vs 24.0% in 9mo) due to operating leverage. R&D expenses also decreased slightly as a percentage of sales.
- Tax Rate: The effective tax rate decreased to 30.5% (Q3) and 33.3% (9mo) from 36.4% and 36.0% respectively, primarily due to a $308,000 benefit from the expiration of statutes of limitations on tax returns under FIN 48.
- Cash Flow: Cash provided by operating activities increased 49% to $21.9M for the nine months, largely due to a $2.4M decrease in inventory compared to a $5.1M increase in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions and Agreements:
- Datascope: Acquired ProGuide catheter assets for ~$3.3M (including future royalties), adding inventory, patents, and goodwill.
- GMA Company: Entered a distribution agreement for a micro-catheter with an initial payment of $500k and potential milestone payments of $1.5M total.
- Lightek: Acquired patent rights for a radio-opaque band with an initial payment of $228k and potential milestone payments.
- Micrus Endovascular (Subsequent Event): Entered a non-binding agreement on Nov 2, 2007, to purchase cardiac and peripheral catheter technology for $3.0M.
- Stock Repurchases: The company repurchased 119,900 shares in Q3 2007 at an average price of $11.20. As of Nov 5, 2007, 1,280,100 shares remained available under the $1.4M repurchase plan approved in April 2007.
- Foreign Currency Risk: Approximately 11.1% of Q3 revenues were denominated in foreign currencies (Euro, GBP, etc.). A stronger foreign currency relative to the USD increased revenues by ~$352k in Q3. The company uses short-term forward contracts to hedge exposure.
- Inventory Obsolescence: Management maintains a reserve of approximately $2.2M for unmarketable or slow-moving inventory. Additional write-downs may be required if market conditions deteriorate.
- Regulatory and Tax Risks: The company is subject to FDA approvals for new products and ongoing tax audits (federal and state years 2002-2006 open). Adoption of FIN 48 resulted in a $610k cumulative adjustment to retained earnings in 2007.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration costs of recent acquisitions (Datascope, GMA, Lightek) in upcoming quarters.
- Margin Sustainability: Monitor whether the Q3 gross margin improvement (39.1%) is sustainable given the headcount and wage increases noted for the nine-month period.
- Inventory Levels: Track inventory turnover and obsolescence reserves, as inventory management was a key driver of the improved cash flow.
- Foreign Exchange Exposure: Assess the impact of currency fluctuations on future earnings, given the ~11% exposure to non-USD revenues.
- Stock Repurchase Activity: Monitor the pace of share buybacks under the remaining $1.28M authorization.
- Tax Position: Review future tax provisions for potential adjustments related to the FIN 48 adoption and ongoing audits.